Protagen AG have been nominated as one of three finalists in the 'Best Personalized Medicine Advance or Application' category of the prestigious Clinical and Research Excellence (CARE) awards
Thursday, 24 March 2016
Protagen AG have been nominated based on the NavigAID Systemic Lupus Erythematosus (SLE) array that was developed using the proprietary Protagen SeroTag® technology.
NavigAID SLE measures autoantibodies associated specifically with SLE and also identifies subsets of autoantibodies associated with particular SLE disease states and pathologies. This is the first time it has been possible to differentiate between different SLE patient subgroups and currently this technology is being applied to the development of an SLE companion diagnostic with a global pharmaceutical partner.
SLE is a systemic autoimmune connective tissue disease. Prevalence is estimated at around 5 million individuals globally, but the disease is difficult to diagnose and treat as it presents itself in a vast array of clinical manifestations. While knowledge of disease mechanisms has been gained there is a great need for novel biomarkers that might help in drug development, disease diagnosis, patient stratification and response prediction. During the last 50 years we have only seen the development of a single new FDA-approved drug for SLE.
The Protagen NavigAID SLE was designed to address these challenges by identifying serum biomarkers that can be used to define SLE subgroups. NavigAID SLE makes possible disease activity assessment, type-I Interferon signature comparison and a unique disease stratification approach to assist with novel drug development. Protagen CEO Stefan Müllner said: “We are proud to have developed technology that can assist in new drug development and we are thrilled for this to have been acknowledged by the panel of judges for the CARE awards."
The awards will be presented on Wednesday 27th April 2016 at the State Room, Boston, MA. To view the 2016 Clinical and Research Excellence Awards finalist, please click here